Enduring Material

- https://usacs.zoom.us/rec/play/w_AxOvii0JzMRYcPWJkRdg-1fdI0Jhc0BVH0RO5ox9D1xzUCgqDszBdyhpXQwEYHJUY6Jt5Jn4bwIK6s.v_EHBpoW_RlN0T3W?eagerLoadZvaPages=sidemenu.billing.plan_management&accessLevel=meeting&canPlayFromShare=true&from=share_recording_detail&continueMode=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Fusacs.zoom.us%2Frec%2Fshare%2FipM_Ed90Dzu_ZoxagpAxAVSNZKId7bDdRjMt4O5WZSqryXQIc8qjStvSk6XnzUWw.vnI_8XGu_Fnr0mW0

• Knowledge in goal directed medical therapy and early identification for sepsis.
• Use of ordersets for sepsis patients in the emergency department, admitted to the hospital, and identified in the hospital after admission.
• Severe Sepsis and Septic Shock Management Bundle (SEP-1) for managing acute sepsis and septic shock.
• CMS requirement for SEP-1 bundle.

• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 0.5 Hour(s) NCPD (ANCC Contact Hours).
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 0.5 Credit(s) IPCE.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 0.5 Hour(s) ACPE.

Sepsis and SEP-1 Criteria

Stephen Feagins, MD and Michael Willing, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Stephen Feagins, MD, Melissa Tillery, RN, MSN, MHA, CPHQ, Leonardo Lozada, MD, and Miranda Mangette have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

This activity is not commercially supported.

75 %

100 %

10/31/2026